Table 2.
Biomarkers significantly affected by colchicine after controlling for false discovery rate.
| Pathway/system | Biomarker | Change for colchicine vs. placebo (95% CI) | Nominal p value |
|---|---|---|---|
| Decreased | |||
| Inflammatory | A1AC | −29.6% (−44.6 to −14.7%) | 0.00031 |
| BPI | −42.6% (−62.8 to −22.4%) | 0.00003 | |
| C5a | −30.9% (−47.9 to −13.9%) | 0.00077 | |
| C9 | −22.3% (−32.7 to −12%) | 0.00010 | |
| Cathepsin E | −14.4% (−24.7 to −4%) | 0.00015 | |
| CD177 | −21.7% (−32.3 to −11.1%) | 0.00001 | |
| COX-2 | −27.1% (−41.2 to −13%) | 0.00042 | |
| C-reactive protein | −33.8% (−48.5 to −19%) | 0.00005 | |
| Cystatin F | −27.5% (−60.4 to +5.4%) | 0.00034 | |
| Haptoglobin | −20.9% (−46.2 to +4.4%) | 0.00082 | |
| HMGN1 | −16.1% (−23.7 to −8.6%) | 0.00012 | |
| IL-6 | −14.8% (−25 to −4.6%) | 0.00040 | |
| IL-16 | −11.5% (−17.8 to −5.2%) | 0.00054 | |
| MMP9 | −29.7% (−48.8 to −10.6%) | 0.00095 | |
| Myeloperoxidase | −33.5% (−45.4 to −21.5%) | 0.00000 | |
| Proteinase 3 | −37.9% (−50.5 to −25.3%) | 0.00000 | |
| Resistin | −21.2% (−27.9 to −14.5%) | 0.00000 | |
| S100A12 | −27.7% (−42.1 to −13.4%) | 0.00041 | |
| SAP | −16.7% (−26.2 to −7.3%) | 0.00099 | |
| SP-D | −49.1% (−74.6 to −23.6%) | 0.00042 | |
| Signaling/transport | ACVR1B | −11.2% (−17.2 to −5.1%) | 0.00067 |
| ASPGR1 | −11.3% (−17.6 to −5%) | 0.00094 | |
| KPNA2 | −10.8% (−16.6 to −5.1%) | 0.00002 | |
| PTK2 | −10% (−22.7 to +2.7%) | 0.00072 | |
| Lipid | LOX-1 | −32.7% (−48.9 to −16.4%) | 0.00026 |
| Smooth muscle relaxation | PDE5A | −14.9% (−20.9 to −8.8%) | 0.00003 |
| Increased | |||
| Cell proliferation | REG4 | +35.6% (5.6 to 65.6%) | 0.00046 |
| Metabolic | ENPP7 | +35% (8 to 62%) | 0.00040 |
| hFABP | +28.5% (11.9 to 45%) | 0.00018 | |
| GDF15 | +23.7% (11.9 to 35.4%) | 0.00003 | |
| Protein folding/transport | PDI | +36.2% (16.6 to 55.8%) | 0.00000 |
| pIgR | +57.2% (9.9 to 104.5%) | 0.00054 | |
| Thrombosis | Protein C | +10.3% (5.5 to 15.2%) | 0.00013 |
| Tissue repair | HGFA | +9.9% (5.3 to 14.5%) | 0.00011 |
Mean percent change from baseline, adjusted for change in placebo.
A1AC alpha 1-antichemotrypsin, BPI Bactericidal permeability-increasing protein, C5a complement component 5a, C9 complement component 9, CD177 cluster of differentiation 177, COX-2 cyclooxygenase-2, HMGN1 high-mobility group nucleosome-binding protein 1, IL interleukin, MMP9 matrix metalloproteinase 9, S100A12 S100 calcium-binding protein A12, SAP serum amyloid P component, SP-D surfactant protein D, ACVR1B activin receptor type-1B, ASPGR1 Asialoglycoprotein receptor 1, KPNA2 karyopherin alpha 2, PTK2 protein tyrosine kinase 2, LOX-1 oxidized low-density lipoprotein receptor 1, ENPP7 ectonucleotide Pyrophosphatase/Phosphodiesterase 7, PDE5A phosphodiesterase 5A, REG4 regenerating islet-derived protein 4, GDF15 growth/differentiation factor 15, hFABP heart-type fatty acid binding protein, PDI protein disulfide-isomerase, pIgR polymeric immunoglobulin receptor, HGFA hepatocyte growth factor activator.